CTLA-4 而非 PD-1 抑制剂诱导的免疫治疗相关 Grover 病 1 例报告：皮肤毒性
A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.
机构信息
Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
Department of Pathology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
出版信息
J Immunother Cancer. 2016 Sep 20;4:55. doi: 10.1186/s40425-016-0157-6. eCollection 2016.
BACKGROUND
Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab.
CASE PRESENTATION
We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis.
CONCLUSION
This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.
背景
免疫相关不良反应（irAEs）是针对 CTLA-4 和 PD-1/PD-L1 的检查点抑制（CPI）疗法的常见副作用。Grover 病是一种罕见的皮肤科疾病，其发病机制尚不清楚，先前曾被报道为 ipilimumab 的 irAE。
病例介绍
我们报告了一例 ipilimumab 诱导的 Grover 病。有趣的是，在我们的患者中，这种皮肤科副作用并没有出现在抗 PD-1 治疗中。进行了免疫分析，提示 Th2 细胞可能在其发病机制中起作用。
结论
本病例提示 Grover 病是 ipilimumab 诱导的 irAE。我们的免疫分析表明，Th2 细胞可能是致病性介质，这需要进一步研究。
Zotero 插件